Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this drug developer would post a loss of $0.05 per share when it actually produced a loss of $0.32, delivering a surprise of -540%. Over the last four quarters, the company ...